EYLEA (AFLIBERCEPT) INJECTION 4U Trademark

Trademark Overview

On Monday, June 10, 2013, a trademark application was filed for EYLEA (AFLIBERCEPT) INJECTION 4U with the United States Patent and Trademark Office. The USPTO has given the EYLEA (AFLIBERCEPT) INJECTION 4U trademark a serial number of 85955455. The federal status of this trademark filing is REGISTERED AND RENEWED as of Wednesday, September 11, 2024. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The EYLEA (AFLIBERCEPT) INJECTION 4U trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

providing medical information and treatment support programs in the nature of medical information via the telephone and the internet for professionals, patients, consumers, and the general public regarding pharmaceutical products and services
eylea (aflibercept) injection 4u

General Information

Serial Number85955455
Word MarkEYLEA (AFLIBERCEPT) INJECTION 4U
Filing DateMonday, June 10, 2013
Status800 - REGISTERED AND RENEWED
Status DateWednesday, September 11, 2024
Registration Number4566649
Registration DateTuesday, July 15, 2014
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 29, 2014

Trademark Statements

Description of MarkThe mark consists of the word "EYLEA" in the color blue with the words "(aflibercept) Injection" in the color black directly below the word "EYLEA". Below and to the right of the words "EYLEA" and "(aflibercept) Injection" are two yellow squares side-by-side. The number "4" in the color blue is contained within the left square and the letter "U" in the color blue is contained within the right square.
Pseudo MarkEYLEA (AFLIBERCEPT) INJECTION FOUR YOU
Indication of Colors claimedThe color(s) blue, black, and yellow is/are claimed as a feature of the mark.
Goods and Servicesproviding medical information and treatment support programs in the nature of medical information via the telephone and the internet for professionals, patients, consumers, and the general public regarding pharmaceutical products and services
NOT AVAILABLE"AFLIBERCEPT INJECTION"

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 19, 2013
Primary Code044
First Use Anywhere DateWednesday, November 30, 2011
First Use In Commerce DateWednesday, November 30, 2011

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Thursday, June 13, 2013NEW APPLICATION ENTERED
Wednesday, June 19, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 20, 2013NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, September 20, 2013ASSIGNED TO EXAMINER
Friday, November 22, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 22, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, November 23, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 25, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, December 29, 2013WITHDRAWN FROM PUB - OG REVIEW QUERY
Thursday, January 9, 2014PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, January 14, 2014NON-FINAL ACTION WRITTEN
Saturday, September 28, 2013NON-FINAL ACTION WRITTEN
Saturday, September 28, 2013NON-FINAL ACTION E-MAILED
Saturday, September 28, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 19, 2013ASSIGNED TO LIE
Thursday, December 19, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, January 14, 2014NON-FINAL ACTION E-MAILED
Tuesday, January 14, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 27, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 26, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, February 27, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 27, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 26, 2014EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 26, 2014EXAMINERS AMENDMENT E-MAILED
Wednesday, March 26, 2014EXAMINER'S AMENDMENT ENTERED
Wednesday, March 26, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 26, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 9, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 29, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 15, 2014REGISTERED-PRINCIPAL REGISTER
Monday, July 15, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Saturday, May 16, 2020TEAS SECTION 8 & 15 RECEIVED
Tuesday, April 29, 2014PUBLISHED FOR OPPOSITION
Tuesday, January 6, 2015TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 6, 2015APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 4, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, August 4, 2020NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Tuesday, August 4, 2020REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, July 14, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 14, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 14, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 27, 2024TEAS SECTION 8 & 9 RECEIVED
Wednesday, September 11, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, September 11, 2024REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Wednesday, September 11, 2024REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Wednesday, September 11, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Saturday, July 15, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

Related Keywords

injection aflibercept eylea medical information public general consumers regarding products services patients pharmaceutical